ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2574

Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation

Mo Yin Mok1, Ka Sin Law2, Wing Yin Kong1, Ge Liu1, Wallace Lau2, C Luo2, FP Huang3, GC Chan4 and Kwok Wah Chan3, 1Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 3Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, 4Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, cytokines, phenotypes, regulatory cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of patients with active systemic lupus erythematosus (SLE), suggesting a role of the IL-33/ST2 axis in the pathogenesis of SLE. This study aims to examine the effect of IL-33 in disease severity of murine lupus.

Methods:

IL-33 was injected intraperitoneally 3 times per week to pre-diseased MRL/lpr mice aged 12 weeks for 6 weeks. Control group was given 1% BSA injection. Urine protein was monitored weekly by albustix and protein assay. Immunophenotyping of splenocytes was examined by flow cytometry. Splenic CD11b+ monocytic cells were isolated by microbeads for mRNA examination.

Results:

IL-33-treated mice (n=9) developed significantly less proteinuria compared to BSA-treated group (n=9). Kidney histology of the IL-33-treated group showed remarkably less mesangial deposit, diffuse proliferative glomerular changes and crescents, and had significantly lower renal composite score compared to controls (median 2.0 vs 9.9, p<0.001). Kidneys of these mice expressed lower mRNA levels of TNF-α (32.1+14.7 vs 77.0+27.8, p<0.001), IL-6 (median 0.6 vs 4.7, p=0.003), IL-1β (31.1+10.1 vs 77.8+24.6, p<0.001) and iNOS (p=0.006). Immunophenotyping of splenocytes showed significantly increased CD4+CD25+ regulatory T (Treg) cells (4.0+1.2% vs 2.2+0.2%, p<0.001) that expressed remarkably higher Foxp3 (76.0+5.0% vs 59.3+12.6%, p=0.002). Splenic extracts showed predominant Gata3 (0.37+0.20 vs 0.12+0.09, p=0.01) and Foxp3 (0.42+0.16 vs 0.17+0.11, p=0.002) mRNA in IL-33-treated mice. These Treg cells expressed high cell surface ST2 (8.9+2.7% vs 4.5+2.0%, p=0.008). There was significant expansion of splenic CD11b+ population in IL-33-treated mice (17.8+10.5 vs 8.8+3.0, p=0.01) that expressed significantly higher CD206 (5.2+0.9% vs 2.9+0.9%, p=0.002). Isolated splenic CD11b+ cells expressed significantly higher mRNA of Arg1, FIZZI and Ym-1 and IL-10 (all p=0.01) with reduced expression of iNOS (p=0.02). Kidney extracts of IL-33 treated mice also had elevated mRNA levels of M2 markers including Arg1 (median 199.8 vs 36.1, p=0.004) and FIZZI (median 25.0 vs 2.7, p<0.001) and reduced MCP-1 (12.7+6.5 vs 35.1+12.0, p<0.001). There was also significantly higher levels of mRNA of Foxp3 (median 43.0 vs 20.8, p=0.006) and Gata 3 (1.7+0.5 vs 0.9+0.5, p=0.008) but lower Rorc (2.6+1.0 vs 3.8+0.8, p=0.008) and Tbx21 (12.6+6.0 vs 29.6+13.7, p=0.003) in the kidneys.

Conclusion:

Exogenous IL-33 led to significantly less proteinuria and renal inflammation. These mice had significantly higher splenic Treg cells with prominent Foxp3 expression. Isolated CD11b+ cells from spleen and kidney extracts demonstrated mRNA levels of M2 macrophage polarisation.


Disclosure: M. Y. Mok, None; K. S. Law, None; W. Y. Kong, None; G. Liu, None; W. Lau, None; C. Luo, None; F. Huang, None; G. Chan, None; K. W. Chan, None.

To cite this abstract in AMA style:

Mok MY, Law KS, Kong WY, Liu G, Lau W, Luo C, Huang F, Chan G, Chan KW. Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interleukin-33-ameliorates-murine-lupus-via-induction-of-regulatory-t-cells-and-m2-macrophage-polarisation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-33-ameliorates-murine-lupus-via-induction-of-regulatory-t-cells-and-m2-macrophage-polarisation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology